EMA/792884/2015

European Medicines Agency decision

P/0299/2015

of 21 December 2015

on the acceptance of a modification of an agreed paediatric investigation plan for C1 inhibitor (human) (Cinryze) (EMEA-000568-PIP01-09-M06) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Contact EMA www.ema.europa.eu/contact

European Medicines Agency decision

P/0299/2015

of 21 December 2015

on the acceptance of a modification of an agreed paediatric investigation plan for C1 inhibitor (human) (Cinryze) (EMEA-000568-PIP01-09-M06) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/193/2009 issued on 2 October 2009, the decision P/114/2010 issued on 7 July 2010, the decision P/32/2011 issued on 28 January 2011, the decision P/0025/2013 issued on 26 February 2013 and the decision P/0164/2013 issued on 29 July 2013,

Having regard to the application submitted by NPS Pharma Holdings Limited on 24 August 2015 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 13 November 2015, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for C1 inhibitor (human) (Cinryze), powder and solvent for solution for injection, intravenous use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to NPS Pharma Holdings Limited, 5 Riverwalk, Citywest Business Campus, 24 – Dublin, Ireland.

Done at London, 21 December 2015

For the European Medicines Agency
Zaïde Frias
Head of Division
Human Medicines Research and Development Support
(Signature on file)

EMA/PDCO/586800/2015
London, 13 November 2015

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-000568-PIP01-09-M06

Scope of the application

Active substance(s):

C1 inhibitor (human)

Invented name:

Cinryze

Condition(s):

Treatment of C1 inhibitor deficiency

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Powder and solvent for solution for injection

Route(s) of administration:

Intravenous use

Name/corporate name of the PIP applicant:

NPS Pharma Holdings Limited

Information about the authorised medicinal product:

See Annex II

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5510
Send a question via our website www.ema.europa.eu/contact

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, NPS Pharma Holdings Limited submitted to the European Medicines Agency on 24 August 2015 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/193/2009 issued on 2 October 2009, the decision P/114/2010 issued on 7 July 2010, the decision P/32/2011 issued on 28 January 2011, the decision P/0025/2013 issued on 26 February 2013 and the decision P/0164/2013 issued on 29 July 2013.

The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 15 September 2015.

Scope of the modification

Some measures of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of C1 inhibitor deficiency

The waiver applies to:

- children from birth to less than 24 months (for treatment of acute attacks), children from birth to less than 6 years (for chronic prophylaxis of acute attacks);
- for powder for solution for injection for intravenous use of C1 inhibitor;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

2. Paediatric Investigation Plan

2.1. Condition:

Treatment of C1 inhibitor deficiency

2.1.1. Indication(s) targeted by the PIP

Treatment of acute attacks in children from 2 to less than 18 years with C1 inhibitor deficiency.

Prevention of angioedema attacks in children from 6 to less than 18 years with C1 inhibitor deficiency with severe or frequent attacks and in whom antifibrinolytics and/or attenuated androgens are ineffective or not indicated.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 2 to less than 18 years.

2.1.3. Pharmaceutical form(s)

Powder for solution for infusion.

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	0	Not applicable.
Non-clinical studies	0	Not applicable.
Clinical studies	4	Study 1 Open-label multicentre acute treatment trial to evaluate safety and efficacy of C1 inhibitor in children and adults as a therapeutic agent for repeated use to treat acute hereditary angioedema attacks. Study 2

		Open-label multicentre acute treatment and chronic prophylaxis trial to evaluate safety and efficacy of C1 inhibitor in children and adults as a therapeutic agent for prevention of hereditary angioedema attacks and to treat acute hereditary angioedema attacks. Study 3 This study was deleted during procedure EMEA-000568-PIP01-09-M04. Study 4 Open label, dose-response trial to evaluate the response and pharmacokinetics/pharmacodynamics of C1 inhibitor for treatment of acute attacks in children less than 12 years of age with hereditary angioedema. Study 5 Single-blind, randomised, multi-centre dose-ranging, crossover study to evaluate the safety and efficacy of CINRYZE for the prevention of angioedema attacks in children from 6 to less than 12 years of age with hereditary angioedema (HAE).
Extrapolation, modelling and simulation studies	0	Not applicable.
Other studies	0	Not applicable.
Other measures	0	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By August 2016
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Treatment of C1-inhibitor deficiency

   Authorised indication:

   - Treatment and pre-procedure prevention of angioedema attacks in adults and adolescents with hereditary angioedema (HAE).
   - Routine prevention of angioedema attacks in adults and adolescents with severe and recurrent attacks of hereditary angioedema (HAE), who are intolerant to or insufficiently protected by oral prevention treatments, or patients who are inadequately managed with repeated acute treatment.

Authorised pharmaceutical formulation(s):

Powder and solvent for solution for injection

Authorised route(s) of administration:

Intravenous use